INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 49m ago
HOUSE PTR9m ago
SEC 13F8m ago
ROBINHOOD CHAIN8m ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Valente Manuela reported SOPH

Chief People Officer · SOPHiA GENETICS SA · SOPHiA GENETICS SA — Share Option (Right to Buy)

Side
M
Value
—
Shares
10.0K
Price
—
Executed
Aug 19, 2026
Disclosed
Aug 21, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Aug 19 executedAug 21, 2026 disclosed

SOPH · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
0/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+1 / 15

    Routine: 7 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SOPH

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    16
    CJ
    Camblong JurgiDirector, Executive Chairman
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$62K
    8,500 sh
    		Oct 12, 2026Oct 14, 2026
    traded Oct 12, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MP
    Menu PhilippeChief Medical Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$36K
    5,000 sh
    		Oct 12, 2026Oct 14, 2026
    traded Oct 12, 2026
    		+2dSEC FORM 4

    Evidence

    13
    XZ
    Xu ZhenyuChief Scientific Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$29K
    4,000 sh
    		Oct 13, 2026Oct 14, 2026
    traded Oct 13, 2026
    		+1dSEC FORM 4

    Evidence

    19
    CJ
    Camblong JurgiDirector, Executive Chairman
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$327K
    40.2K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    16
    MR
    Muken RossDirector, Chief Executive Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$80K
    9,838 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    13
    CG
    Cardoza GeorgeChief Financial Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$13K
    1,592 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    16
    VD
    Van Well DaanChief Legal Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$50K
    6,168 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    13
    VM
    Valente ManuelaChief People Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$34K
    4,240 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    16
    MP
    Menu PhilippeChief Medical Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$60K
    7,394 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    29
    PK
    Puylaert KevinChief Sales Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale
    		SELL$1,491
    185 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    13
    VA
    Verma AbhimanyuChief Technology Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$43K
    5,284 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    29
    PK
    Puylaert KevinChief Sales Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale
    		SELL$246
    31 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    16
    XZ
    Xu ZhenyuChief Scientific Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$60K
    7,394 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MR
    Muken RossDirector, Chief Executive Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$3,515
    422 sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    13
    CG
    Cardoza GeorgeChief Financial Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$6,447
    774 sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    29
    MP
    Menu PhilippeChief Medical Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale
    		SELL$39K
    5,000 sh
    		Sep 14, 2026Sep 16, 2026
    traded Sep 14, 2026
    		+2dSEC FORM 4

    Evidence

    13
    XZ
    Xu ZhenyuChief Scientific Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$32K
    4,000 sh
    		Sep 14, 2026Sep 16, 2026
    traded Sep 14, 2026
    		+2dSEC FORM 4

    Evidence

    16
    CJ
    Camblong JurgiDirector, Executive Chairman
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$65K
    8,500 sh
    		Sep 10, 2026Sep 14, 2026
    traded Sep 10, 2026
    		+4dSEC FORM 4

    Evidence

    13
    VD
    Van Well DaanChief Legal Officer
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$47K
    6,168 sh
    		Sep 11, 2026Sep 14, 2026
    traded Sep 11, 2026
    		+3dSEC FORM 4

    Evidence

    23
    HL
    Hibbs Kathy LDirector
    SOPHSOPHiA GENETICS SA
    Open-market sale · 10b5-1 plan
    		SELL$51K
    6,250 sh
    		Sep 8, 2026Sep 10, 2026
    traded Sep 8, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001840706-26-000293
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 19, 2026
    Published
    Aug 21, 2026
    Ingested by INSIDER
    Nov 5, 02:21 UTC
    Last re-read
    Nov 5, 02:21 UTC

    Extracted facts

    Filer
    Valente Manuela
    Role
    Chief People Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    SOPHiA GENETICS SA — Share Option (Right to Buy)
    Ticker
    SOPH
    Shares
    10.0K
    Price per share
    $0
    Execution date (reported)
    Aug 19, 2026
    Owned after transaction
    0 shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    What this establishes

    Valente Manuela filed this Form 4 reporting a option exercise of SOPH on Aug 19, 2026. It became public on Aug 21, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief People Officer
    Valente Manuelacik:0002009280
    Issuer
    SOPHiA GENETICS SAcik:0001840706

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.